March 1, 2024 10:50 AM EST
News Briefing

Achieve Life Sci­ences nabs $124M; Pierre Fab­re buys pan-RAF pro­gram from Kin­nate

Jaimy Lee

Deputy Editor

Plus, news about Tar­sus Phar­ma­ceu­ti­cals, Hu­ma­cyte, Stem­cell Tech­nolo­gies and SQZ Biotech­nolo­gies:

Achieve Life Sci­ences rais­es $124M, de­tails plans for NDA: The com­pa­ny

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times